A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Hepatocellular Carcinoma Clinical Trial

Official title:

A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer Manifestations

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03781934
• Other study ID #: MIV-818-101/201
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: September 5, 2018
• Est. completion date: February 29, 2024

Study information

• Verified date: September 2023
• Source: Medivir
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2) pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients with various solid tumours that have spread to the liver, or alternatively originating in the liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only include patients with HCC.

Description:

This study will be conducted in three phases. The initial phase, 1a, will enroll up to 12 subjects and include a total of one dose escalation per patient. Once pre-defined criteria for starting phase 1b monotherapy has been met among the enrolled patients in phase 1a, the next phase of the study will be initiated. Phase 1b monotherapy will enroll up to 30 patients in a 3+3 design with interpatient dose escalations. All dose escalation decisions will be made by a safety review committee that will meet regularly during the study conduct. When the MTD has been established, the SRC will provide a RP2D for monotherapy. Phase 1b combination constitutes an interpatient dose escalation to identify the RP2D for MIV-818 when used in combination with 1) lenvatinib and 2) pembrolizumab therapy. This part of the study will enroll up to 36 patients in a 3+3 design with interpatient dose escalations. Safety review will be performed by the SRC to determine the RP2D of MIV 818 for use in combination with lenvatinib and pembrolizumab. The SRC may recommend that the selected dose of MIV-818 is further evaluated in up to 30 patients in the Phase 2a expansion part of the study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 53
• Est. completion date: February 29, 2024
• Est. primary completion date: February 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Male or female = 18 years of age on the day of signing informed consent.

2. Able to understand and voluntarily sign a written informed consent and is willing, and able, to comply with the protocol requirements.

3. Must have measurable disease based on RECIST v1.1 as determined by the site study team. Must have at least 1 target lesion in the liver. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

4. Must have a Child-Pugh A status for Phase 1a and a Child-Pugh A or B status for Phase 1b and 2a. SRC discretion to restrict to Child-Pugh A status for Phase 1b and 2a.

5. Must have an ECOG performance status of 0 or 1 at Screening.

6. Must have life expectancy of > 12 weeks in the investigator's opinion.

7. Must have ALT and AST = 5.0 × upper limit of normal (ULN) at Screening.

8. Must have total bilirubin (TBil) = 3.0 mg/dL at Screening.

9. Must have adequate renal function with estimated creatinine clearance = 60 mL/min (based on Cockcroft and Gault formula or similar) at Screening

10. Must have platelets = 75,000/mL at Screening.

11. Must have International Normalized Ratio (INR) = 1.7 at Screening. Female who is postmenopausal, OR Female who is of childbearing potential (postmenarchal) who agrees to use a highly efficient method of contraception (ie, a method with less than 1% failure rate [eg, sterilization, hormone implants, hormone injections, intrauterine devices, or vasectomized partner or combined birth control pills]) from Screening until 90 days after the final dose of MIV-818. OR Male who agrees to use condoms from Screening until 90 days after the final dose of MIV-818. OR Male with a female partner of childbearing potential (WOCBP) who is using a highly efficient method of contraception as described above.

13. WOCBP must have a negative serum pregnancy test at Screening and negative (serum or urine) pregnancy test within 72 h before the first study drug dose.

Phase 1a and 1b specific Inclusion Criteria:

14. Must have progressed on or are intolerant of standard therapy with:

1. Histologically or cytologically confirmed HCC, including fibrolamellar HCC; patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and the medical monitor, or

2. Histologically or cytologically confirmed iCCA, or

3. Liver metastases from colon, rectal, or gastric solid tumors with limited extrahepatic tumor burden (any extrahepatic metastases should be limited to 1 other site and a maximum of 1 target lesion outside the liver).

Phase 1b Monotherapy-specific Inclusion Criterion:

15. Must have:

1. Histologically or cytologically confirmed HCC, including fibrolamellar HCC; patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and the medical monitor, or

2. Histologically or cytologically confirmed iCCA, or

3. Liver metastases from solid tumors, with limited extrahepatic tumor burden (i.e. no brain or bone metastases), any extrahepatic metastases should be limited to 1 other site and a maximum of 1 target lesion outside the liver).

Combination therapy-specific Inclusion Criterion:

16. Must have histologically or cytologically confirmed HCC that is considered advanced or unresectable, i.e. not suitable for either surgery, radiofrequency ablation (RFA) or loco-regional therapies (patients with HCC that received their diagnosis according to the agreed international radiological guideline are also admissible upon agreement between the investigator and medical monitor). Patients with fibrolamellar HCC or a mixed HCC and iCCA will be excluded.

17. Must have progressed on or are intolerant of 1or 2 lines of standard therapy for HCC (see also exclusion criterion no. 20) and are now candidates for lenvatinib or pembrolizumab treatment.

Exclusion Criteria:

1. Tumor volume exceeding 50% of liver.

2. History of previous malignancy within the last 5 years except basal cell carcinoma or carcinoma in situ in solid organ.

3. Known CNS or brain metastases, unless previously treated and stable for 3 months.

4. Ongoing significant disease other than target disease as judged by the investigator to compromise the patients' ability to complete this study.

5. History of solid organ transplant or bone marrow transplant.

6. Receiving immunosuppressive therapy including oral corticosteroids.

7. Active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) and patients with active hepatitis C (eg, hepatitis C RNA is [qualitative] detected).

8. Positive human immunodeficiency virus (HIV) infection.

9. Poorly controlled ascites and/or requirement for therapeutic paracentesis more frequently than once every 3 months.

10. Symptomatic encephalopathy within 3 months prior to Screening and/or requirement for medication for encephalopathy.

11. Esophageal variceal bleeding within 2 weeks prior to Screening.

12. Receiving prior anticancer therapy within 4 weeks prior to first dose of MIV-818.

13. Receiving any other investigational agent within 4 weeks prior to Screening

14. Enrolled in another clinical study with an investigational drug.

15. Presence of residual toxicities of CTCAE Grade > 1 after prior anticancer therapy within 2 weeks of first treatment with MIV-818, except for alopecia.

16. History of allergic reactions attributed to compounds of similar chemical or biological composition to MIV-818.

17. HCC of diffuse infiltrative type.

18. Receiving drugs that are extensively metabolized by cytochrome P450 (CYP) 3A4 that have a narrow therapeutic index. Drugs that are extensively metabolized by CYP3A4 that have a narrow therapeutic index must be discontinued 5 half-lives before first dose of MIV-818. Combination therapy-specific Exclusion Criteria: Patients are excluded from combination therapy parts of this study if any of the

following criteria are met:

19. Patients with a diagnosis of fibrolamellar HCC.

20. Received >2 lines of therapy for the treatment of advanced HCC.

21. Systolic blood pressure (BP) =160 mmHg or diastolic BP =100 mmHg despite optimal anti-hypertensive therapy and with no change in anti hypertensive agents within the last 1 week prior to Screening.

22. Women who are breastfeeding.

23. Bleeding disorders or receiving anti-coagulation drugs.

24. Any interventional treatment for esophageal varices required within 28 days of study treatment.

25. Hepatic encephalopathy in the last 6 months.

26. QTc interval is greater than 480 milliseconds at Screening.

27. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

28. Has an active infection requiring systemic therapy.

Exclusion criteria applicable to pembrolizumab cohort only:

29. Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to planned start of study therapy.

30. Presence of known active tuberculosis (TB; Bacillus tuberculosis).

31. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

32. Known history of, or any evidence of active, non-infectious pneumonitis or has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.

Exclusion criterion applicable to lenvatinib cohort only:

33. Proteinuria > 1g / 24 hours. Patients with > 1+ proteinuria on dipstick testing will need a 24-hour urine protein measured to exclude proteinuria > 1g / 24 hours.

Related Conditions & MeSH terms

• Cholangiocarcinoma
• Hepatocellular Carcinoma
• Intrahepatic Cholangiocarcinoma
• Liver Metastases
• Liver Neoplasms

Intervention

Drug:
• MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
MIV-818 - oral capsules; pembrolizumab - IV
• MIV-818 (fostroxacitabine bralpamide) + lenvatinib
MIV-818 - oral capsules; lenvatinib - oral capsules

Locations

Country	Name	City	State
Belgium	Antwerp University Hospital	Antwerp
Belgium	University Hospitals Gasthuisberg	Leuven
Korea, Republic of	CHA Bundang Medical Center	Gyeonggi-do
Korea, Republic of	Pusan National University Hospital	Pusan
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Samsung Medical Center	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Severance Hospital	Seoul
Spain	Hospital Clinic Carrer Rosselló 161	Barcelona
Spain	Hospital Vall Hebrón	Barcelona
Spain	START Barcelona HM Nou Delfos	Barcelona
Spain	Hospital General Universitario Gregorio Marañón	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	START Madrid-FJD	Madrid
United Kingdom	Beatson West of Scotland Cancer Care	Glasgow
United Kingdom	Guy's Hospital, Oncology and Clinical Trials	London
United Kingdom	Northern Institute for Cancer Research	Newcastle Upon Tyne
United Kingdom	Chruchill Hospital, Cancer and Haematology Centre	Oxford

Sponsors (1)

Lead Sponsor	Collaborator
Medivir

Countries where clinical trial is conducted

Belgium,  Korea, Republic of,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and Severity of Adverse Events (AEs)	Percentage of participants with an adverse event, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0	Participants monitored throughout treatment period and during follow-up, up to 6 months
Primary	Incidence and magnitude of clinically significant changes in red blood cell count, white blood cell count and platelet count	Change from baseline	Participants monitored throughout treatment period and during follow-up, up to 6 months
Primary	Incidence and magnitude of clinically significant changes in aspartate aminotransferase (AST) and alanine aminotransferase (ALT)	Change from baseline	Participants monitored throughout treatment period and during follow-up, up to 6 months
Primary	Incidence and magnitude of clinically significant changes in bilirubin	Change from baseline	Participants monitored throughout treatment period and during follow-up, up to 6 months
Primary	Incidence of clinically significant changes in vital sign - Systolic and diastolic blood pressure	Millimeter of mercury (mmHg)	Participants monitored throughout treatment period and during follow-up, up to 6 months
Primary	Incidence of clinically significant changes in vital sign - Pulse rate	Beats per minute (BPM)	Participants monitored throughout treatment period and during follow-up, up to 6 months
Primary	Incidence of clinically significant changes in vital sign - Body Temperature	Celsius (°C)	Participants monitored throughout treatment period and during follow-up, up to 6 months
Primary	Incidence of clinically significant changes in vital signs - Weight	Kilograms (kg)	Participants monitored throughout treatment period and during follow-up, up to 6 months
Primary	Incidence of clinically significant changes in ECGs	QT interval (milli second (ms))	Participants monitored throughout treatment period and during follow-up, up to 6 months
Secondary	Preliminary efficacy by means of RECIST evaluation	ORR will be assessed by monitoring tumor response and progression using RECIST v1.1; ORR will be assessed by monitoring tumor response and progression using mRECIST; ORR will be assessed by monitoring tumor response and progression using RECIST v 1.1 in liver lesions only	Participants monitored throughout treatment period every 6 weeks until disease progression, up to 6 months
Secondary	Plasma levels of a fetoprotein (AFP)		Participants monitored throughout treatment period every 6 weeks until disease progression, up to 6 months